Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5

作者：

Cao, Yi ^{[1
,2
]}

Li, Yunjin ^{[1
,2
]}

Liu, Ruijie ^{[1
]}

Zhou, Jianhua ^{[1
,2
]}

Wang, Kuansong ^{[1
,2
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China

[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China

来源：

CANCERS | 2023年 / 15卷 / 09期

基金：

中国国家自然科学基金;

关键词：

HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;

D O I：

10.3390/cancers15092568

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.

引用

页数：27

共 137 条

[31] Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors [J].

Floros, Konstantinos, V ;

Jacob, Sheeba ;

Kurupi, Richard ;

Fairchild, Carter K. ;

Hu, Bin ;

Puchalapalli, Madhavi ;

Koblinski, Jennifer E. ;

Dozmorov, Mikhail G. ;

Boikos, Sosipatros A. ;

Scaltriti, Maurizio ;

Faber, Anthony C. .

CELL DEATH & DISEASE, 2021, 12 (02)

[32] Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer [J].

Gaibar, Maria ;

Beltran, Laura ;

Romero-Lorca, Alicia ;

Fernandez-Santander, Ana ;

Novillo, Apolonia .

JOURNAL OF ONCOLOGY, 2020, 2020

[33] Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant [J].

Gao, Zhichao ;

Xu, Junnan ;

Wang, Yan ;

Wu, Jie ;

Sun, Tao .

FRONTIERS IN ONCOLOGY, 2021, 11

[34] A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade [J].

Geuijen, Cecile ;

Tacken, Paul ;

Wang, Liang-Chuan ;

Klooster, Rinse ;

van Loo, Pieter Fokko ;

Zhou, Jing ;

Mondal, Arpita ;

Liu, Yao-bin ;

Kramer, Arjen ;

Condamine, Thomas ;

Volgina, Alla ;

Hendriks, Linda J. A. ;

van der Maaden, Hans ;

Rovers, Eric ;

Engels, Steef ;

Fransen, Floris ;

den Blanken-Smit, Renate ;

Zondag-van der Zande, Vanessa ;

Basmeleh, Abdul ;

Bartelink, Willem ;

Kulkarni, Ashwini ;

Marissen, Wilfred ;

Huang, Cheng-Yen ;

Hall, Leslie ;

Harvey, Shane ;

Kim, Soyeon ;

Martinez, Marina ;

O'Brien, Shaun ;

Moon, Edmund ;

Albelda, Steven ;

Kanellopoulou, Chrysi ;

Stewart, Shaun ;

Nastri, Horacio ;

Bakker, Alexander B. H. ;

Scherle, Peggy ;

Logtenberg, Ton ;

Hollis, Gregory ;

de Kruif, John ;

Huber, Reid ;

Mayes, Patrick A. ;

Throsby, Mark .

NATURE COMMUNICATIONS, 2021, 12 (01)

[35] Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].

Geyer, Charles E. ;

Forster, John ;

Lindquist, Deborah ;

Chan, Stephen ;

Romieu, C. Gilles ;

Pienkowski, Tadeusz ;

Jagiello-Gruszfeld, Agnieszka ;

Crown, John ;

Chan, Arlene ;

Kaufman, Bella ;

Skarlos, Dimosthenis ;

Campone, Mario ;

Davidson, Neville ;

Berger, Mark ;

Oliva, Cristina ;

Rubin, Stephen D. ;

Stein, Steven ;

Cameron, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743

[36] Systemic Therapy for Advanced Human 3 Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update [J].

Giordano, Sharon H. ;

Temin, Sarah ;

Chandarlapaty, Sarat ;

Crews, Jennie R. ;

Kirshner, Jeffrey J. ;

Krop, Ian E. ;

Lin, Nancy U. ;

Patt, Debra A. ;

Perlmutter, Jane ;

Ramakrishna, Naren ;

Davidson, Nancy E. ;

Franzoi, Maria Alice B. ;

Anders, Carey K. ;

Ikawa, Aki .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) :2612-+

[37] Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer [J].

Gonzalez-Angulo, A. M. ;

Blumenschein, G. R., Jr. .

CANCER TREATMENT REVIEWS, 2013, 39 (04) :313-320

[38] Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition [J].

Gu, Chang-ling ;

Zhu, Hai-xia ;

Deng, Lan ;

Meng, Xiao-qing ;

Li, Kai ;

Xu, Wei ;

Zhao, Le ;

Liu, Yue-qin ;

Zhu, Zhen-ping ;

Huang, Hao-min .

ACTA PHARMACOLOGICA SINICA, 2022, 43 (03) :672-680

[39] Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance) [J].

Haddad, Tufia C. ;

He, Jun ;

O'Sullivan, Ciara C. ;

Chen, Beiyun ;

Northfelt, Donald ;

Dueck, Amylou C. ;

Ballman, Karla V. ;

Tenner, Kathleen S. ;

Linden, Hannah ;

Sparano, Joseph A. ;

Hopkins, Judith O. ;

De Silva, Chamath ;

Perez, Edith A. ;

Haluska, Paul ;

Goetz, Matthew P. .

BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (02) :477-487

[40]

Hamilton EP, 2020, J CLIN ONCOL, V38

← 1 2 3 4 5 6 7 8 9 10 →